Taken together, these findings suggest that TNF inhibitors remain promising therapeutic reagents for severe asthma, but inhibition of TNF alone may not be sufficient to fully control the disease pathology and also may lead to serious side effects, which are mediated by overexpression of other proinflammatory cytokines. This evidence concerns the gene TNF and asthma.